Results 81 to 90 of about 9,620 (237)
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims Risk minimization measures (RMMs) are key regulatory tools to ensure safe medicinal product use. Regulatory guidelines recommend pre‐specifying the targets, or ‘thresholds’, for assessing RMM effectiveness. We aimed to review recent industry‐sponsored post‐authorization safety studies (PASS) that evaluated the effectiveness of RMMs ...
Kexin Zhu +7 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aim This study aimed to compare how Norwegian healthcare professionals (HCPs) and consumers reported the same adverse event (AE) following immunization with vaccines against COVID‐19 during the COVID‐19 pandemic. Specifically, we aimed to compare the extent to which HCPs and consumers reported information relevant for assessing the causal relationship ...
Tommy Emil Dzus +4 more
wiley +1 more source
Toward clone‐on‐a‐chip: Ethical and legal considerations for organ‐on‐a‐chip evolution
BMEMat, EarlyView.The term “clone‐on‐a‐chip (CoC)” is introduced as a conceptual warning for personalized organ‐on‐a‐chip platforms and not to suggest technological feasibility, where a CoC ethical discussion extends beyond issues arising from the requirements for informed consent, property rights, commercialization efforts, and cell sourcing to include potentially ...
Muhammed Erkan Karabekmez +6 more
wiley +1 more source
Counting cases, conserving species: addressing highly pathogenic avian influenza in wildlife
Biological Reviews, EarlyView.ABSTRACT Highly pathogenic avian influenza (HPAI) has become a critical threat to wildlife, shifting from a seasonal epizootic to a persistent, year‐round panzootic with global consequences. Here, we summarise the origin, evolutionary mechanisms, and expanding host range of the current H5N1 virus (clade 2.3.4.4b) and assess its impact on wildlife. Over
Ulrich Knief +4 more
wiley +1 more source
Status and future of recombinant adeno‐associated virus vector manufacturing
Biotechnology Progress, EarlyView.Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley +1 more source
Fungal Antimicrobial Resistance: Mechanisms, Drivers, and Global Clinical Burden
ChemFoodChem, EarlyView.ABSTRACT Fungal antimicrobial resistance (AMR) is a growing concern for world health caused by an increase in multidrug‐resistant infections, an increase in environmental reservoirs, and the ineffectiveness of current antifungal treatments. Fungal infections continue to be largely excluded from AMR initiatives while causing over 1.6 million deaths ...
Bikash Baral
wiley +1 more source
PERFECTA Loaded Lipid Cubosomes for 19F‐MRI: Physico‐Chemical Characterization
Chemistry – A European Journal, EarlyView.Phytantriol‐based cubosomes loaded with PERFCTA, a fluorinated MRI probe, were developed as promising systems for imaging and drug delivery. The nanoparticles showed high PERFECTA encapsulation efficiency, strong fluorine MRI signals, and optimal colloidal stability in biological media.
Pietro Milesi +10 more
wiley +1 more source
Pro-Vaccination Flu and COVID-19 Messages: Evidence of Congenial Targeted and Spillover Effects
COVIDGiven the plentitude of messages in the public arena that promote vaccination against different diseases or raise the possibility of vaccine mandates, we asked whether message effects in one disease domain might spill over into other domains.
James Price Dillard, Lijiang Shen
doaj +1 more source
Digital Transformation of Medicines Regulation in Africa—Perspectives from a Stakeholder Convening
Clinical Pharmacology &Therapeutics, EarlyView.Regulatory authorities worldwide are developing strategies to integrate artificial intelligence (AI) into the lifecycle of health products, technologies, and medicines. While regulators share goals of improving efficiency, strengthening decision‐making, and protecting public health, their approaches differ according to institutional structures ...
Christelna Reyneke +12 more
wiley +1 more source
Cytometry Part B: Clinical Cytometry, EarlyView.Abstract Our knowledge of the immune system continues to expand at a rapid pace, and this coupled with technological advances now enables us to interrogate both the breadth and the depth of the immune response at levels without precedent. This has also facilitated rapidly integrating some of this carefully vetted knowledge into clinical practice ...
Aaruni Khanolkar, Aisha Ahmed
wiley +1 more source